Learning Objectives:

  1. Discuss the non-T cell inflamed and T cell inflamed tumor phenotypes and the role of β-catenin in the non-T cell inflamed phenotype.
  2. Discuss the rationale for targeting the β-catenin pathway involved in regulating immune cell responses to tumor.
  3. Discuss novel high throughput screening methods to identify small molecules that target the β-catenin pathway to promote anti-tumor immune responses.

  and

Learning Objectives:

  1. Understand the rationale for measuring minimal residual disease (MRD) in multiple myeloma (MM)
  2. Review the advantages and limitations of the techniques used to measure MRD in MM
  3. Discuss novel high throughput screening methods to identify small molecules that target the β-catenin pathway to promote anti-tumor immune responses.
Session date: 
Monday, October 15, 2018 - 12:00pm to 1:00pm
Speaker Name: 
Brian L. Heiss, MD, MA and Benjamin J. Derman, MD
Location: 
UCMC
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.